Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis
Ananthakrishnan AN, Korzenik JR, Hur C

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22416019

DOI
10.1002/ibd.22951

Indexing Status
Subject indexing assigned by NLM

MeSH
Anti-Inflammatory Agents, Non-Steroidal /economics /therapeutic use; Antibodies, Monoclonal /economics /therapeutic use; Biological Therapy /economics; Cost-Benefit Analysis; Crohn Disease /drug therapy /economics /surgery; Decision Support Techniques; Follow-Up Studies; Hospitalization /economics /statistics & numerical data; Humans; Infliximab; Mucous Membrane /pathology; Prognosis; Prospective Studies; Quality-Adjusted Life Years; Wound Healing

AccessionNumber
22013010444

Date bibliographic record published
05/04/2013